India's Eris Lifesciences gains on strong quarterly results
BUZZ-India's Eris Lifesciences gains on strong quarterly results ** Shares of Eris Lifesciences ERIS.NS rise to 2.4% to 1,122.70 rupees
** Pharmaceuticals co says September-quarter consolidated net profit increased y/y 53%, consolidated revenue increased about 13%
** Says won approval to conduct Phase 1 and Phase 3 trials for India's first recombinant semaglutide, a diabetes and weight-loss drug
** Stock rated "buy" on avg by 11 analysts, with median PT of 1,670 rupees - data compiled by LSEG
** Stock down about 26% YTD
(Reporting by Anushka Rajvedi in Bengaluru)
((mailto: anushka.rajvedi@thomsonreuters.com))
Recent news on Eris Lifesciences
See all newsIndia's Eris Lifesciences gains on strong quarterly results
Brief: Eris Lifesciences Sept-Quarter Consol Net Profit 1.84 Billion Rupees
Brief: Eris Lifesciences Says Krishnakumar Vaidyanathan Resigns As Executive Director & COO
Brief: Eris Lifesciences Ltd Says June-Quarter Consol Net Profit 1.42 Billion Rupees
Brief: Eris Lifesciences March-Quarter Consol Net Profit 2.82 Billion Rupees